WO2026040955 - USE OF BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX
National phase entry is expected:
Publication Number
WO/2026/040955
Publication Date
26.02.2026
International Application No.
PCT/CN2025/115327
International Filing Date
18.08.2025
Title **
[English]
USE OF BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX
[French]
UTILISATION D'UN COMPLEXE POLYPEPTIDIQUE ANTI-CD3/CD20 BISPÉCIFIQUE
[Chinese]
双特异性抗CD3/CD20多肽复合物的用途
Applicants **
SHANGHAI CHIA TAI TIANQING PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Inventors
YANG, Anqi
ZHAO, Wei
YU, Ding
ZHANG, Xiquan
WANG, Xunqiang
HU, Yu
Priority Data
202411133708.4
19.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1970 | |
| EPO | Filing, Examination, Granting | 14624 | |
| Japan | Filing, Examination, Granting | 2325 | |
| South Korea | Filing, Examination, Granting | 2441 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
26,100
Contact Us
Abstract[English]
The present application discloses a pharmaceutical combination comprising a bispecific anti-CD3/CD20 polypeptide complex and a second therapeutic agent, and use thereof in the preparation of a drug for treating non-Hodgkin lymphoma.[French]
La présente demande concerne une combinaison pharmaceutique comprenant un complexe polypeptidique anti-CD3/CD20 bispécifique et un second agent thérapeutique, et son utilisation au cours de la préparation d'un médicament pour le traitement d'un lymphome non hodgkinien.[Chinese]
本申请公开了一种包括双特异性抗CD3/CD20多肽复合物和第二治疗剂的药物组合，及其在制备治疗非霍奇金淋巴瘤的药物中的用途。